COVID-19 Resources


(Courtesy of WE-REACH collaborator, the UW Entrepreneurial Law Clinic)

  • BIO Summary of CARES Act is an overview of key provisions that relate to life science companies, and provides an initial list of essential businesses with life science and medical supply chain exemptions.
  • The Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services received $2B to invest in research and development of vaccines, therapeutics, and diagnostics to combat COVID-19. BARDA is pursuing the following: vaccines, diagnostics, potential therapeutics, ventilators, immunomodulators or therapeutics targeting lung repair, pre- and post-exposure prophylaxis, and respiratory protective devices.
  • BARDA DRIVe Accelerator provides technical and financial resources to entrepreneurs whose ideas have the potential to transform emergency preparedness, detection, and response. Life Science Washington Institute has been selected as one of 13 sites in the DRIVe Accelerator Network to help identify relevant researchers and companies and connect them with the DRIVe team.
  • Coronavirus Funding Monitor is a centralized portal of current funding opportunities for the research community. It offers a curated list of open funding calls and other support for researchers, non-profit organizations, and commercial organizations, specifically for COVID-19 and coronavirus-related research and treatment.
  • FDA Template for Diagnostics EUA is a COVID-19 Emergency Use Authorization (EUA) template for diagnostic developers, available upon request. Sponsors interested in potential EUA for tests to detect COVID-19 may contact CDRH-EUA-Templates@fda.hhs.gov. COVID-19 molecular assays for mature, FDA-cleared, widely placed devices are of great interest to the FDA.
  • Gates-Wellcome Trust-Mastercard COVID-19 Therapeutics Accelerator is providing an additional commitment of $150 million in seed funding to accelerate the development of therapeutics for COVID-19. The accelerator aims to identify, assess, develop, and scale up treatments. The foundation will also leverage a portion of its $2.5 billion Strategic Investment Fund, which uses a suite of financial tools to address market failures and incentivize private enterprise to develop affordable and accessible health products.
  • The Division of Innovation and Industrial Partnerships invites U.S.-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the ability to respond to the COVID-19 crisis.
  • Workers and facilities supporting essential research, development, operations and clinical trials, including biotech therapies, are deemed essential.
  • InfoEd Global, a provider of software that supports the Electronic Research Administration, has compiled a library of COVID-19 funding opportunities and resources.